This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.
Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.
Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.
Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction
by Zacks Equity Research
Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.
Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.
Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3
Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.
Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
by Zacks Equity Research
Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Biotech ETFs in Focus on String of Q3 Earnings Beat
by Zacks Equity Research
Biotech ETFs draw attention post impressive Q3 results.
Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up
by Zacks Equity Research
Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3
by Zacks Equity Research
Intercept's (ICPT) revenues beat estimates, owing to strong Ocaliva sales in the third quarter of 2018.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
by Zacks Equity Research
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
Can the Strong Economy Save the Stock Market?
by John Blank
The U.S. economy is the MOST important fundamental.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $70.90, marking a +1.66% move from the previous day.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).